Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Correlations between the level of biomarkers in CSF /serum and DPR . (a) The level of bFGF in CSF was negatively correlated with DPR of ALS patients. (b) The correlation between the bFGF level in serum and DPR was negative. (c) The level of VEGF in CSF was negatively correlated with DPR of ALS patients. (d) The correlation between the VEGF level in serum and DPR was negative. (e) The level of MIP ‐1α in CSF was negatively correlated with DPR of ALS patients. (f) The correlation between the MIP ‐1α level in serum and DPR was negative. (g) The level of MCP ‐1 in CSF was positively correlated with DPR of ALS patients. (h) The correlation between the MCP ‐1 level in serum and DPR was positive. (i) The level of IFN ‐γ in CSF was positively correlated with DPR of ALS patients. (j) The correlation between the IFN ‐γ level in serum and DPR was positive

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques:

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Correlations between the level of biomarkers in CSF /serum and duration. (a) The level of bFGF in CSF was positively correlated with the duration of ALS patients. (b) The correlation between the bFGF level in serum and duration was positive. (c) The level of VEGF in CSF was positively correlated with the duration of ALS patients. (d) The correlation between the VEGF level in serum and duration was positive. (e) The level of MIP ‐1α in CSF was positively correlated with the duration of ALS patients. (f) The correlation between the MIP ‐1α level in serum and duration was positive

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques:

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Biomarker levels in the CSF and serum of patients with ALS and control subjects

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques: Biomarker Assay

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Correlations between biomarker levels and disease duration in ALS patients

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques: Biomarker Assay

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Correlations between biomarker levels and ALSFRS‐r scores in ALS patients

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques: Biomarker Assay

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Correlations between biomarker levels and DPR in ALS patients

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques: Biomarker Assay

Journal: Brain and Behavior

Article Title: Evaluating the levels of CSF and serum factors in ALS

doi: 10.1002/brb3.637

Figure Lengend Snippet: Analysis of the survival of ALS patients using univariate and multivariate Cox proportional hazards models

Article Snippet: The serum and CSF samples were detected for the following 13 factors: IL‐2 (R&D, D2050), IL‐6 (R&D, D6050), IL‐10 (R&D, D1000B), IL‐15 (R&D, D1500), IL‐17 (R&D, D1700), G‐CSF (R&D, DCS50), GM‐CSF (R&D, DGM00), bFGF (R&D, DFB50), VEGF (R&D, DVE00), MIP‐1α (R&D, DMA00), MIP‐1β (R&D, DMB00), MCP‐1 (R&D, DCP00), and IFN‐γ (R&D, DIF50).

Techniques:

Journal: International Journal of Oncology

Article Title: Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway

doi: 10.3892/ijo.2021.5239

Figure Lengend Snippet: PAI-1 is the key factor secreted by TAMs following CAF-CM stimulation and promotes tumor malignant behavior in vitro . (A) Original image and (B) spot pixel value from a cytokine array revealed the profiles of paracrine factors in the M0-CM, TAM (Ca)-CM and TAM(CAF)-CM. (C) Western blot and (D) ELISA results indicated that PAI-1 was upregulated in the TAM(CAF) group compared with that in the M0 and TAM(Ca) groups. (E) Cell Counting Kit-8 and (F) colony formation assays showed that the inhibition of PAI-1 in TAM(CAF)-CM suppressed the enhanced proliferation of Huh-7 cells. (G) Wound healing (scale bar, 400 µ m) and (H) Transwell and (I) Matrigel (scale bar, 200 µ m) assays indicated that the inhibition of PAI-1 in the TAM(CAF)-CM group suppressed the enhanced migration and invasion of the Huh-7 cells. * P<0.05; ** P<0.01. CAF, cancer-associated fibroblast; CM, conditioned medium; CXCL12, C-X-C motif chemokine ligand 12; CXCL5, C-X-C motif chemokine ligand 5; PAI-1, plasminogen activator inhibitor-1; PDGF-AA, platelet derived growth factor-AA; TAM, tumor-associated macrophage; TIM-3, T-cell immunoglobulin mucin 3; M0, macrophages; NS, not significant.

Article Snippet: The Human IL-6 Quantikine ELISA kit (cat. no. D6050), Human Serpin E1/PAI-1 Quantikine ELISA kit (cat. no. DSE100) and Human CXCL12/stromal cell-derived factor 1α Quantikine ELISA kit (cat. no. DSA00) were purchased from R&D Systems Inc., to detect the concentrations of IL-6, PAI-1 and CXCL12 in the CM, according to the manufacturer's instructions.

Techniques: In Vitro, Western Blot, Enzyme-linked Immunosorbent Assay, Cell Counting, Inhibition, Migration, Derivative Assay

Journal: International Journal of Oncology

Article Title: Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway

doi: 10.3892/ijo.2021.5239

Figure Lengend Snippet: CAF-derived CXCL12 induces the secretion of PAI-1 in TAM(CAF). (A) Original image and (B) spot pixel value from a cytokine array to identify the different patterns of molecules in cancer-CM and CAFs-CM. CXCL12 gene expression and its secretion were increased in CAFs compared with that in the Huh-7 and Lx-2 cells following (C) RT-qPCR and (D) ELISA. (E) CXCR4 gene expression in M0, TAM(Ca) and TAM(CAF) was analyzed using RT-qPCR. (F) RT-qPCR and (G) ELISA results demonstrated that the gene expression level and secretion of PAI-1 were decreased in TAM(CAF) after CXCL12 neutralization in CAF-CM, respectively. (H) Schematic representation of the proposed interactions between HCC, TAMs and CAFs. * P<0.05; ** P<0.01. CAF, cancer-associated fibroblast; CM, conditioned medium; CCL5, C-C motif chemokine ligand 5; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C Motif chemokine receptor 4; HCC, hepatocellular carcinoma; HSCs, hepatic stellate cells; PAI-1, plasminogen activator inhibitor-1; PDGF-AA, platelet derived growth factor-AA; RT-qPCR, reverse transcription-quantitative PCR; TAM, tumor-associated macrophage; Ab, antibody.

Article Snippet: The Human IL-6 Quantikine ELISA kit (cat. no. D6050), Human Serpin E1/PAI-1 Quantikine ELISA kit (cat. no. DSE100) and Human CXCL12/stromal cell-derived factor 1α Quantikine ELISA kit (cat. no. DSA00) were purchased from R&D Systems Inc., to detect the concentrations of IL-6, PAI-1 and CXCL12 in the CM, according to the manufacturer's instructions.

Techniques: Derivative Assay, Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Neutralization, Reverse Transcription, Real-time Polymerase Chain Reaction